(Press-News.org) Contact information: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Dana-Farber Cancer Institute
Antipsychotic drug exhibits cancer-fighting properties
In zebrafish model, perphenazine activates therapeutic pathway for intractable leukemia, may hold promise for other tumors
BOSTON, Jan. 9, 2014 - In a prime example of finding new uses for older drugs, studies in zebrafish show that a 50-year-old antipsychotic medication called perphenazine can actively combat the cells of a difficult-to-treat form of acute lymphoblastic leukemia (ALL). The drug works by turning on a cancer-suppressing enzyme called PP2A and causing malignant tumor cells to self-destruct.
The findings suggest that developing medications that activate PP2A, while avoiding perphenazine's psychotropic effects, could help clinicians make much-needed headway against T-cell ALL, and perhaps other tumors as well.
A study team led by Alejandro Gutierrez, MD, and A. Thomas Look, MD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and Jon Aster, MD, PhD, of Dana-Farber Cancer Institute and Brigham and Women's Hospital, reported the results Jan. 9 in the Journal of Clinical Investigation.
T-ALL is rarer and more aggressive than the B-cell form of ALL, and it has a relatively poor prognosis. Despite improvements in the treatments available, 20 percent of children and more than 50 percent of adults diagnosed with T-ALL succumb to it.
To identify possible new treatment options, Gutierrez, Look and their collaborators screened a library of 4,880 compounds—including FDA-approved drugs whose patents had expired, small molecules and natural products—in a model of T-ALL engineered using zebrafish.
Strategies that identify new uses for existing drugs have grown in popularity in recent years as a way of quickly developing new disease therapies. Zebrafish models are cost-effective platforms for rapidly conducting drug screens, as well as basic stem cell, genetic, cancer and developmental research.
"We wanted to see if there were drugs or known bioactive molecules that are active against T-ALL that hadn't been tested yet," Look explained. "There may be drugs available for other indications that could be readily repurposed if we can show activity."
One of the strongest hits in the zebrafish screen was the drug perphenazine. It is a member of the phenothiazines, a family of antipsychotic medications used for 50 years, because they can block dopamine receptors.
The team verified perphenazine's anti-leukemic potential in vitro in several mouse and human T-ALL cell lines. Biochemical studies indicated that perphenazine's anti-tumor activity is independent of its psychotropic activity, and that it attacks T-ALL cells by turning on PP2A.
The fact that perphenazine works by reactivating a protein shut down in cancer cells is itself novel in the drug development field.
"We rarely find potential drug molecules that activate an enzyme," Gutierrez explained. "Most new drugs deactivate some protein or signal that the cancer cell requires to survive. But, here, perphenazine is restoring the activity of PP2A in the T-ALL cell."
Gutierrez and Look, along with their collaborators, are now working to better understand the interactions between PP2A and perphenazine. They also want to search for or develop molecules that bind to and activate the enzyme more tightly and specifically to avoid perphenazine's psychiatric effects.
"The challenge is to use medicinal chemistry to develop new PP2A inhibitors similar to perphenazine and the other phenothiazines, but to dial down dopamine interactions and accentuate those with PP2A," Look said.
The researchers see future PP2A inhibitors not as magic bullets but as potentially important additions to the oncologist's arsenal when treating patients with T-ALL.
" T-ALL patients are often on the borderline between a long remission and a cure," Look said. "If we can push the leukemia cells a little harder, we may get more patients who are actually cured. In this way, PP2A inhibitors may, in combination with other drugs, make a real difference for patients."
It may be that the benefits of PP2A-activating drugs could extend beyond T-ALL. "The proteins that PP2A suppresses, such as Myc and Akt, are involved in many tumors," Look noted. "We are optimistic that PP2A activators will have quite broad activity against different kinds of cancer, and we're anxious to study the pathway in other malignancies as well."
###
This study was supported by the National Cancer Institute (grant numbers K08CA133103 and P01CA109901), the Leukemia and Lymphoma Society, the William Lawrence Blanche Hughes Foundation, the Bear Necessities Foundation, the Ligue Nationale contre le Cancer, Association Laurette Fugain, Institut National du Cancer (INCA), Universités Paris Diderot and Paris Sud, INSERM, CEA and Canceropole Ile de France, European Union's Seventh Framework Programme and the American Society of Hematology.
The Dana-Farber/Boston Children's Cancer and Blood Disorders Center brings together two internationally known research and teaching institutions that have provided comprehensive care for pediatric oncology and hematology patients since 1947. The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and outpatient care at the Dana-Farber Cancer Institute's Jimmy Fund Clinic. Dana-Farber/Boston Children's brings the results of its pioneering research and clinical trials to patients' bedsides through five clinical centers: the Blood Disorders Center, the Brain Tumor Center, the Hematologic Malignancies Center, the Solid Tumors Center, and the Stem Cell Transplant Center.
Antipsychotic drug exhibits cancer-fighting properties
In zebrafish model, perphenazine activates therapeutic pathway for intractable leukemia, may hold promise for other tumors
2014-01-10
ELSE PRESS RELEASES FROM THIS DATE:
Some motor proteins cooperate better than others
2014-01-10
Some motor proteins cooperate better than others
Rice University researchers view competition, cooperation among motors in live cells
HOUSTON - (Jan. 9, 2014) - Rice University researchers have engineered cells to characterize how sensitively altering the cooperative functions of ...
ORNL-UT researchers invent 'sideways' approach to 2-D hybrid
2014-01-10
ORNL-UT researchers invent 'sideways' approach to 2-D hybrid
OAK RIDGE, Tenn., Jan. 9, 2014 -- Researchers at the Department of Energy's Oak Ridge National Laboratory and the University of Tennessee, Knoxville have pioneered a new technique for forming ...
Hubble probes interior of Tarantula Nebula
2014-01-10
Hubble probes interior of Tarantula Nebula
Like lifting a giant veil, the near-infrared vision of NASA's Hubble Space Telescope uncovers a dazzling new view deep inside the Tarantula Nebula. Hubble reveals a glittering treasure trove of more than ...
Hubble views stellar genesis in the Southern Pinwheel
2014-01-10
Hubble views stellar genesis in the Southern Pinwheel
A photogenic and favorite target for amateur astronomers, the full beauty of nearby barred spiral galaxy M83 is unveiled in all of its glory in this Hubble Space Telescope mosaic image. The ...
Novel biomarker approach suggests new avenues to improve schizophrenia disease management
2014-01-10
Novel biomarker approach suggests new avenues to improve schizophrenia disease management
Environmental effects of events such as oxygen deprivation and infections may be preserved as markers in blood that are associated to schizophrenia, according to an ...
Stem cells injected into nerve guide tubes repair injured peripheral nerve
2014-01-10
Stem cells injected into nerve guide tubes repair injured peripheral nerve
Putnam Valley, NY. (Jan. 9, 2014) – Using skin-derived stem cells (SDSCs) and a previously developed collagen tube designed to successfully bridge gaps in injured ...
Are you listening? Kids' ear infections cost health care system nearly $3 billion a year
2014-01-10
Are you listening? Kids' ear infections cost health care system nearly $3 billion a year
Acute otitis media, or ear infection, is the most common ailment among kids of preschool age and younger in the U.S., primarily because these children ...
NIH-created toxin can kill HIV-infected cells that persist despite treatment
2014-01-10
NIH-created toxin can kill HIV-infected cells that persist despite treatment
Approach could potentially be part of future HIV cure strategy
A team including University of North Carolina and NIH scientists has demonstrated in ...
Researchers develop tool to determine individual risk of prostate cancer overdiagnosis
2014-01-10
Researchers develop tool to determine individual risk of prostate cancer overdiagnosis
Nomogram aims to enable informed decision-making and personalized treatment
SEATTLE - Studies have found that prostate cancer is overdiagnosed in up to 42 percent ...
Study: Athlete's first reaction in victory is dominance
2014-01-10
Study: Athlete's first reaction in victory is dominance
Body language, also called 'triumph,' stronger in victors from cultures that emphasize hierarchy
SAN FRANCISCO -- Upon victory, an athlete's initial and instinctive reaction is one that displays dominance ...
LAST 30 PRESS RELEASES:
Major review highlights latest evidence on real-time test for blood – clotting in childbirth emergencies
Inspired by bacteria’s defense strategies
Research spotlight: Combination therapy shows promise for overcoming treatment resistance in glioblastoma
University of Houston co-leads $25 million NIH-funded grant to study the delay of nearsightedness in children
NRG Oncology PREDICT-RT study completes patient accrual, tests individualized concurrent therapy and radiation for high-risk prostate cancer
Taking aim at nearsightedness in kids before it’s diagnosed
With no prior training, dogs can infer how similar types of toys work, even when they don’t look alike
Three deadliest risk factors of a common liver disease identified in new study
Dogs can extend word meanings to new objects based on function, not appearance
Palaeontology: South American amber deposit ‘abuzz’ with ancient insects
Oral microbes linked to increased risk of pancreatic cancer
Soccer heading does most damage to brain area critical for cognition
US faces rising death toll from wildfire smoke, study finds
Scenario projections of COVID-19 burden in the US, 2024-2025
Disparities by race and ethnicity in percutaneous coronary intervention
Glioblastoma cells “unstick” from their neighbors to become more deadly
Oral bacterial and fungal microbiome and subsequent risk for pancreatic cancer
New light on toxicity of Bluefin tuna
Menopause drug reduces hot flashes by more than 70%, international clinical trial finds
FGF21 muscle hormone associated with slow ALS progression and extended survival
Hitting the right note: The healing power of music therapy in the cardiac ICU
Cardiovascular disease risk rises in Mexico, despite improved cholesterol control
Flexible optical touch sensor simultaneously pinpoints pressure strength and location
Achalasia diagnosis simplified to AI plus X-ray
PolyU scholars pioneer smart and sustainable personal cooling technologies to address global extreme heat
NIH grant aims for childhood vaccine against HIV
Menstrual cycle and long COVID: A relation confirmed
WMO report on global water resources: 2024 was characterized by both extreme drought and intense rainfall
New findings explain how a mutation in a cancer-related gen causes pulmonary fibrosis
Thermal trigger
[Press-News.org] Antipsychotic drug exhibits cancer-fighting propertiesIn zebrafish model, perphenazine activates therapeutic pathway for intractable leukemia, may hold promise for other tumors